My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

11.15 -0.19 (-1.63%)
Streaming Delayed Price Updated: 12:40 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
 
Via Benzinga
7 Analysts Assess Regenxbio: What You Need To Know
 
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts
 
Via Benzinga
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
Regenxbio reported sustained biomarker reduction and positive neurodevelopmental outcomes in the pivotal CAMPSIITE trial of RGX-121 for MPS II. 
Via Benzinga
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients. 
Via Benzinga
Analyst Expectations For Regenxbio's Future
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
What to Expect from Regenxbio's Earnings
 
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
 
Via Benzinga
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls
REGENXBIO Q2 2025 earnings miss estimates with $21.36M revenue and -$1.38 EPS. Stock drops 2.3% pre-market amid clinical pipeline updates for DMD and diabetic retinopathy therapies. 
Via Chartmill
Topics Earnings
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts
 
Via Benzinga
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
 
Via Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch. 
Via Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase
 
Via Benzinga
Topics Stocks
Which stocks are gapping on Thursday?
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
The One-Minute Market Report - Saturday, April 26
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, ETFs, and stocks that moved the market higher, as well as the market segments that defied the... 
Via Talk Markets
Topics ETFs Stocks / Equities
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile. 
Via Benzinga
Signet Jewelers, BGM Group, StoneCo, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts
 
Via Benzinga
Earnings Scheduled For March 13, 2025
 
Via Benzinga
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.